Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019


#179322

N/A

GBI Research

$ 3500

In Stock


GBI Research has released the pharmaceutical report - “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”. The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.

Scope

  • A brief introduction to prostate cancer, including the disease’s pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.
  • In-depth analysis of drugs available for the treatment of prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
  • Comprehensive review of the pipeline for prostate cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
  • Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth.
  • Discussion of the licensing and co-development deals landscape in prostate cancer, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals.

Reasons to Buy

  • Understand the different levels of prostate cancer therapies, from early-stage prostate cacner to metastatic and castrate-resistant prostate cancer.
  • Understand the vast scope and diversity of the pipeline, including which molecule types and mechanisms of action are prominent.
  • Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for prostate cancer therapeutics.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the prostate cancer therapeutics market.
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Strong Growth Expected in Prostate Cancer Market
2.2 Novel Therapies Offer New Hope for Prostate Cancer Treatment
2.3 Large Pipeline, but High Failure Rate

3 Introduction
3.1 Pathophysiology and Etiology
3.2 Epidemiology
3.3 Disease Progression
3.4 Treatment

4 Marketed Products
4.1 Hormonal Therapies
4.1.1 Zoladex (Goserelin) – AstraZeneca
4.1.2 Lupron Depot (Leuprolide acetate) – Abbvie
4.1.3 Triptorelin
4.1.4 Firmagon (degarelix) – Ferring
4.1.5 Casodex (Bicalutamide)
4.1.6 Summary
4.2 Chemotherapy agents
4.2.1 Taxotere (Docetaxel) – Sanofi
4.2.2 Jevtana (Cabazitaxel) – Sanofi
4.3 Therapeutic Vaccines
4.3.1 Provenge (sipuleucel-T) – Dendreon
4.4 Targeted therapies (Second Generation Anti-androgens)
4.4.1 Zytiga (Abiraterone acetate) – Janssen
4.4.2 Xtandi (Enzalutamide) – Astellas/Medivation
4.5 Bone Metastasis Treatments
4.5.1 Xofigo (Radium 223) – Bayer/Algeta
4.5.2 Xgeva (denosumab) – Amgen
4.5.3 Zometa (zoledronic acid) – Novartis
4.6 Heat Map for Marketed Products

5 Prostate Cancer Developmental Pipeline
5.1 Overall Pipeline
5.2 Mechanisms of Action
5.3 Clinical Trials
5.3.1 Attrition Rate
5.3.2 Enrollment
5.3.3 Duration
5.4 Key Late-Stage Pipeline Molecules
5.4.1 Cometriq (Cabozantinib) – Exelixis
5.4.2 OGX-011 (custirsen sodium) – Teva
5.4.3 TAK-700 (orteronel) – Takeda
5.4.4 ProstAtak (AdvTk+ valcyclovir) – Advantagene
5.4.5 ProstVac – Bavarian Nordic
5.4.6 Tasquinimod – Active Biotech
5.4.7 Yervoy (Ipilimumab) – Bristol-Myers Squibb
5.4.8 ARN-509 – Aragon Pharmaceuticals, Johnson and Jonhson

6 Market Forecast to 2019
6.1 Global
6.1.1 Treatment Usage Patterns
6.1.2 Market Size
6.2 North America
6.2.1 US
6.2.2 Canada
6.3 Five European Markets
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 Japan
6.4.1 Treatment Usage Patterns
6.4.2 Market Size

7 Prostate cancer therapeutics: Drivers and barriers
7.1 Drivers
7.1.1 Major Unmet Treatment Needs of Late Stage Prostate Cancer Patients
7.1.2 Increasing Disease Population
7.1.3 New Drugs Entering the Market
7.1.4 Rapid and Robust Uptake of Recently Approved High-Cost Therapies
7.1.5 Rapid Inflation Rate for Specialty Pharmaceutical Products in the US
7.1.6 Market Capture of Previously Untreated Patient Segments
7.2 Barriers
7.2.1 Uncertain Treatment Algorithm
7.2.2 Uptake Limited by High Prices for New Products
7.2.3 Patent Expiry of Taxotere
7.2.4 Intensifying Competition Acting as a Barrier to Market Capture

8 Licensing and Co-development Deals Analysis
8.1 Licensing Deals
8.1.1 Algeta Enters into Licensing Agreement with Bayer Schering for Xofigo
8.1.2 Sanofi-Aventis Enters into a Licensing Agreement with Oxford BioMedica
8.1.3 Novacea Enters Into Licensing Agreement With Schering-Plough For Asentar
8.1.4 Teva Pharma Enters into a Licensing Agreement with Oncogenex Pharma for OGX-011
8.1.5 Hoffman La Roche Enters into a Licensing Agreement with Inovio Pharmaceuticals for Prostate Cancer and Hepatitis B Immunotherapy Products
8.1.6 Colby Pharmaceutical Company Enters into a Licensing Agreement with MannKind for Cancer Immunotherapy Products
8.1.7 Ipsen Enters into a Licensing Agreement with GTx
8.1.8 Protox Therapeutics Enters into a Licensing Agreement with Kissei Pharma
8.1.9 AEterna Zentaris Enters Into License And Collaboration Agreement With Nippon Kayaku For Ozarelix
8.1.10 Orion Corporation Enters Into Agreement With Indevus Pharmaceuticals
8.2 Co-Development Deals
8.2.1 Medivation Enters into Co-Development Agreement with Astellas Pharma
8.2.2 Takeda Pharma Enters into an Agreement with Cell Genesys
8.2.3 Active Biotech Enters into Co-Development Agreement with Ipsen

9 Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Sources
9.4 Sources for Marketed Products Heat Map
9.5 Scientific Support
9.6 Research Methodology
9.6.1 Coverage
9.6.2 Secondary Research
9.6.3 Therapeutic Landscape
9.6.4 Epidemiology-Based Forecasting
9.6.5 Market Size by Geography
9.6.6 Geographical Landscape
9.6.7 Pipeline Analysis
9.6.8 Competitive Landscape
9.6.9 Expert Panel Validation
9.7 All Publicly Announced Pipeline Products, by Phase
9.7.1 Discovery
9.7.2 Preclinical/IND-Filed
9.7.3 Phase I
9.7.4 Phase II
9.7.5 Phase III/Pre-Registration
9.7.6 Undisclosed Stage of Development
9.8 Tabular Forecast Data
9.8.1 Global
9.8.2 US
9.8.3 UK
9.8.4 France
9.8.5 Germany
9.8.6 Italy
9.8.7 Spain
9.8.8 Japan
9.8.9 Canada
9.9 Disclaimer

Table 1: Prostate Cancer Therapeutics, Prostate Cancer Risk Factors
Table 2: Prostate Cancer Therapeutics, Prostate Cancer Staging
Table 3: Prostate Cancer Therapeutics, Abbreviations
Table 4: Prostate Cancer Therapeutics, Sources for Heat Map
Table 5: Prostate Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 6: Prostate Cancer Therapeutics, Global, All Pipeline Products (Preclinical/IND Filed), 2013
Table 7: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013
Table 8: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 9: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase III/Pre-Registration), 2013
Table 10: Prostate Cancer Therapeutics, Global, All Pipeline Products (Undisclosed Stage of Development), 2013
Table 11: Prostate Cancer, Leading Eight Markets, Market Forecast, 2012–2019
Table 12: Prostate Cancer, US, Market Forecast, 2012–2019
Table 13: Prostate Cancer, UK, Market Forecast, 2012–2019
Table 14: Prostate Cancer, France, Market Forecast, 2012–2019
Table 15: Prostate Cancer, Germany, Market Forecast, 2012–2019
Table 16: Prostate Cancer, Italy, Market Forecast, 2012–2019
Table 17: Prostate Cancer, Spain, Market Forecast, 2012–2019
Table 18: Prostate Cancer, Japan, Market Forecast, 2012–2019
Table 19: Prostate Cancer, Canada, Market Forecast, 2012–2019

Figure 1: Prostate Cancer Therapeutics: Percentage of Men Diagnosed with Prostate Cancer in the US, by Age, 2005–2009
Figure 2: Prostate Cancer Therapeutics: Average Number of New Cases and Age-Specific Incidence Rates per 100,000 Population, UK, 2008–2010
Figure 3: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stages I and II)
Figure 4: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stage III)
Figure 5: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stage IV)
Figure 6: Prostate Cancer Therapeutics, Sales of Zoladex ($m), 2000–2012
Figure 7: Prostate Cancer Therapeutics, Sales of Lupron Depot ($m), 2009–2012
Figure 8: Prostate Cancer Therapeutics, Sales of Taxotere ($bn), 2004–2012
Figure 9: Prostate Cancer Therapeutics: Heat Map (mCRPC)
Figure 10: Market for Prostate Cancer, Global, Pipeline Overview, 2013
Figure 11: Market for Prostate Cancer, Global, Mechanisms of Action, 2013
Figure 12: Market for Prostate Cancer, Global, Clinical Trial Failure Rates, 2006–2013
Figure 13: Market for Prostate Cancer, Global, Clinical Trial Failure Rates (Molecule Type), 2006–2013
Figure 14: Market for Prostate Cancer, Global, Clinical Trial Failure Rates (Mechanism of Action), 2006–2013
Figure 15: Market for Prostate Cancer, Global, Clinical Trial Enrollment by Product (Molecule Type), 2006–2013
Figure 16: Market for Prostate Cancer, Global, Clinical Trial Enrollment by Product (Mechanism of Action), 2006–2013
Figure 17: Market for Prostate Cancer, Global, Clinical Trial Duration (Molecule Type), 2006–2013
Figure 18: Market for Prostate Cancer, Global, Clinical Trial Duration (Mechanism of Action), 2006–2013
Figure 19: Prostate Cancer Therapeutics: Top Eight Major Markets, Prevalence Populations, 2012–2019
Figure 20: Prostate Cancer Therapeutics: Top Eight Major Markets, Market Forecast ($bn), 2012–2019
Figure 21: Prostate Cancer Therapeutics, US, Treatment Usage Patterns, 2012–2019
Figure 22: Prostate Cancer Therapeutics: US, Market Forecast ($m), 2012–2019
Figure 23: Market for Prostate Cancer Therapeutics to 2019, Canada, Treatment Usage Patterns, 2012–2019
Figure 24: Prostate Cancer Therapeutics: Canada, Market Size ($m), 2012–2019
Figure 25: Prostate Cancer Therapeutics: Leading Five European Markets, Treatment Usage Patterns, 2012–2019
Figure 26: Prostate Cancer Therapeutics: Leading Five European Markets, Annual Cost of Therapy, 2012–2019
Figure 27: Prostate Cancer Therapeutics: Leading Five European Countries, Market Size ($m), 2012–2019
Figure 28: Prostate Cancer Therapeutics: Japan, Treatment Usage Patterns, 2012–2019
Figure 29: Prostate Cancer Therapeutics: Japan, Market Size ($m), 2012 – 2019
Figure 30: Market for Prostate Cancer, Global, Licensing Deals, 2006–2012
Figure 31: Market for Prostate Cancer, Global, Licensing Deals, 2006–2012
Figure 32: Market for Prostate Cancer, Global, Licensing Deals, 2006–2012
Figure 33: Market for Prostate Cancer, Global, Co-Development Deals, 2006–2012
Figure 34: Market for Prostate Cancer, Global, Co-Development Deals, 2006–2012
Figure 35: GBI Research Market Forecasting Model